Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95


The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells.

Li S, Liang Y, Wu M, Wang X, Fu H, Chen Y, Wang Z.

Cancer Cell Int. 2013 Mar 28;13:30. doi: 10.1186/1475-2867-13-30. eCollection 2013.


RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer.

Wang ZG, Fukazawa T, Nishikawa T, Watanabe N, Sakurama K, Motoki T, Hatakeyama S, Omori O, Ohara T, Tanabe S, Fujiwara Y, Takaoka M, Shirakawa Y, Yamatsuji T, Tanaka N, Naomoto Y.

Oncol Rep. 2010 Apr;23(4):1167-72.


Inhibition of mammalian target of rapamycin signaling by CCI-779 (temsirolimus) induces growth inhibition and cell cycle arrest in Cashmere goat fetal fibroblasts (Capra hircus).

Wang Z, Liu T, Chen Y, Zhang X, Liu M, Fu H, Liu D.

DNA Cell Biol. 2012 Jun;31(6):1095-9. doi: 10.1089/dna.2011.1559. Epub 2012 Feb 9.


TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells.

Wang ZG, Fukazawa T, Nishikawa T, Watanabe N, Sakurama K, Motoki T, Takaoka M, Hatakeyama S, Omori O, Ohara T, Tanabe S, Fujiwara Y, Shirakawa Y, Yamatsuji T, Tanaka N, Naomoto Y.

Oncol Rep. 2008 Dec;20(6):1473-7.


Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.

Lin F, Zhang PL, Yang XJ, Prichard JW, Lun M, Brown RE.

Ann Clin Lab Sci. 2006 Summer;36(3):283-93.


The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.

Zhao H, Cui K, Nie F, Wang L, Brandl MB, Jin G, Li F, Mao Y, Xue Z, Rodriguez A, Chang J, Wong ST.

Breast Cancer Res Treat. 2012 Jan;131(2):425-36. doi: 10.1007/s10549-011-1420-7. Epub 2011 Mar 11.


Mammalian target of rapamycin: a new molecular target for breast cancer.

Mita MM, Mita A, Rowinsky EK.

Clin Breast Cancer. 2003 Jun;4(2):126-37. Review.


Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.

Peralba JM, DeGraffenried L, Friedrichs W, Fulcher L, Grünwald V, Weiss G, Hidalgo M.

Clin Cancer Res. 2003 Aug 1;9(8):2887-92.


mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.

Yu K, Toral-Barza L, Discafani C, Zhang WG, Skotnicki J, Frost P, Gibbons JJ.

Endocr Relat Cancer. 2001 Sep;8(3):249-58.


mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.

Ishikawa D, Takeuchi S, Nakagawa T, Sano T, Nakade J, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Nakamura T, Matsumoto K, Kagamu H, Yoshizawa H, Yano S.

PLoS One. 2013 May 14;8(5):e62104. doi: 10.1371/journal.pone.0062104. Print 2013.


Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.

Márk Á, Hajdu M, Váradi Z, Sticz TB, Nagy N, Csomor J, Berczi L, Varga V, Csóka M, Kopper L, Sebestyén A.

BMC Cancer. 2013 May 22;13:250. doi: 10.1186/1471-2407-13-250.


A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.

Shor B, Zhang WG, Toral-Barza L, Lucas J, Abraham RT, Gibbons JJ, Yu K.

Cancer Res. 2008 Apr 15;68(8):2934-43. doi: 10.1158/0008-5472.CAN-07-6487.


Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells.

Fei SJ, Zhang XC, Dong S, Cheng H, Zhang YF, Huang L, Zhou HY, Xie Z, Chen ZH, Wu YL.

PLoS One. 2013 Jul 16;8(7):e69104. doi: 10.1371/journal.pone.0069104. Print 2013.


The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.

Hidalgo M, Rowinsky EK.

Oncogene. 2000 Dec 27;19(56):6680-6. Review.


Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.

Hosoi H, Dilling MB, Shikata T, Liu LN, Shu L, Ashmun RA, Germain GS, Abraham RT, Houghton PJ.

Cancer Res. 1999 Feb 15;59(4):886-94.


Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells.

Ohara T, Takaoka M, Toyooka S, Tomono Y, Nishikawa T, Shirakawa Y, Yamatsuji T, Tanaka N, Fujiwara T, Naomoto Y.

Cancer Sci. 2011 Jul;102(7):1344-9. doi: 10.1111/j.1349-7006.2011.01967.x. Epub 2011 Jun 2.


Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.

Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, Milella M.

Cancer Res. 2006 Jun 1;66(11):5549-54.


Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice.

Nishikawa T, Takaoka M, Ohara T, Tomono Y, Hao H, Bao X, Fukazawa T, Wang Z, Sakurama K, Fujiwara Y, Motoki T, Shirakawa Y, Yamatsuji T, Tanaka N, Fujiwara T, Naomoto Y.

Cancer Biol Ther. 2013 Mar;14(3):230-6. doi: 10.4161/cbt.23294. Epub 2013 Jan 4.


Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.

Weekes CD, Song D, Arcaroli J, Wilson LA, Rubio-Viqueira B, Cusatis G, Garrett-Mayer E, Messersmith WA, Winn RA, Hidalgo M.

Neoplasia. 2012 Aug;14(8):690-701.


Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.

Zhou Q, Lui VW, Lau CP, Cheng SH, Ng MH, Cai Y, Chan SL, Yeo W.

Biochem Pharmacol. 2012 May 1;83(9):1146-58. doi: 10.1016/j.bcp.2012.01.013. Epub 2012 Jan 20.

Items per page

Supplemental Content

Support Center